Erk5 Antibody [B13D22]

Katalog-Nr. F4696

Drucken

Biologische Beschreibung

Spezifität Erk5 Antibody [B13D22] weist endogene Spiegel des gesamten Erk5-Proteins nach.
Hintergrund Erk5 (extrazelluläre signalregulierte Kinase 5, MAPK7/BMK1) ist die größte klassische MAPK, die sich durch eine einzigartige ~400 Aminosäuren lange C-terminale Extension jenseits ihrer N-terminalen Kinasedomäne auszeichnet. Sie enthält eine kanonische TEY-Aktivierungsschleife (Thr218-Glu219-Tyr220) im Kinasekern sowie spezifische Andockoberflächen für die PB1-Domäne von MEK5 und das lineare D-Motiv, die eine spezifische Assemblierung getrennt von ERK1/2 ermöglichen. Der C-terminale Schwanz beherbergt ein nukleäres Lokalisierungssignal (NLS), eine Transaktivierungsdomäne und eine auto-inhibitorische KIM-Andockstelle, die gemeinsam den nukleären Transport und die transkriptionelle Aktivität regulieren. Die duale Phosphorylierung des TEY-Motivs durch MEK5 hebt die C-terminale Autoinhibition auf, wodurch das NLS für die nukleäre Translokation freigelegt wird, wo Erk5 direkt MEF2C/2D an Ser289/396 phosphoryliert, um die Myozyten-Enhancer-Faktor-abhängige Transkription fetaler Herzgene (wie NPPA und MEF2C) zu fördern. Der C-Schwanz scaffoldiert auch MEF2 über nicht-katalytische Verknüpfung und erfährt eine Autophosphorylierung an Ser731/750, um die Expression von Zielgenen zu verstärken. Im Zytosol aktiviert Erk5 die ribosomale S6-Kinase und unterstützt die Endothelbarrierefunktion über Aktin-Remodellierung, wobei eine Feedback-Dephosphorylierung durch PP2C/PP1-Phosphatasen und Dual-Spezifitäts-MAPK-Phosphatasen erfolgt. Erk5-Knockout-Mäuse zeigen embryonale Letalität aufgrund von Gefäßdefekten und Herzfehlbildungen durch fehlgeschlagene Endothelmigration und MEF2C-Derepression. Die somatische Hyperaktivierung von Erk5 treibt die Progression von Brust- und Prostatakrebs durch MEF2-vermittelte Proliferation und Metastasierung voran und trägt zur pathologischen Herzhypertrophie über eine drucküberlastungsinduzierte MEF2-Aktivierung bei.

Nutzungsinformationen

Anwendung WB Verdünnung
WB
1:1000
Reaktivität Human, Mouse, Rat, Monkey
Quelle Rabbit Monoclonal Antibody MW 115 kDa
Lagerpuffer PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
Lagerung
(Ab dem Datum des Erhalts)
-20°C (avoid freeze-thaw cycles), 2 years
WB
Experimental Protocol:
 
Sample preparation
1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature.
2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) and put the sample on ice for 5 min.
3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) and put the sample on ice for 5 min.
4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
5. Remove a small volume of lysate to determine the protein concentration;
6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
 
Electrophoretic separation
1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 5%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
 
Transfer membrane
1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
Recommended conditions for wet transfer: 200 mA, 120 min.
( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
 
Block
1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
2. Incubate the film in the blocking solution for 1 hour at room temperature;
3. Wash the film with TBST for 3 times, 5 minutes each time.
 
Antibody incubation
1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
2. Wash the film with TBST 3 times, 5 minutes each time;
3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
 
Antibody staining
1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.

Referenzen

  • https://pubmed.ncbi.nlm.nih.gov/23656407/
  • https://pubmed.ncbi.nlm.nih.gov/22800864/

Anwendungsdaten

WB

Validiert von Selleck

  • F4696-wb
    Lane 1: L929, Lane 2: A172, Lane 3: K562